Activity of the French Economic and Public Health Evaluation Committee (CEESP): Retrospective of 10 Years of Economic Assessment on Health Products
Author(s)
Noemie Pouxviel, PharmD, Laetitia Rey, PharmD, Marguerite Kandel, PhD, Sandy Leproust, PhD.
IQVIA, Courbevoie, France.
IQVIA, Courbevoie, France.
OBJECTIVES: Since the introduction of economic assessment of health products in France in 2014 (via Decree no. 2012-1116 of October 2nd, 2012, eligibility criteria modified in 2023), the Economic and Public Health Evaluation Committee (CEESP) has issued economic opinions on cost-effectiveness and budget impact analyses of drugs or medical devices. This study provides a 10-years retrospective analysis of CEESP’s activity, emphasizing on methodologies and outcomes of economic evaluations.
METHODS: Data were extracted from the IQVIA's internal exhaustive database covering CEESP’s opinions published between 2014 and 31st December 2024. The analysis included number and types of evaluations, therapeutic areas and in-depth description of methodological reservations or global major uncertainty as defined by the CEESP’s doctrine.
RESULTS: Since 2014, CEESP has published 236 opinions with an average of 21 opinions per year, predominantly on medicines and vaccines (91%). A downward trend is observed since 2023 related to changes in eligibility criteria. Furthermore, 41% of the medicines and vaccines cost-utility analysis (CUA) were invalidated since 2014: 34% due to major methodological reservations (primarily related to clinical data integration and utility scores measurement) and 7% due to global major uncertainty. For validated CUA, the median ICER was €126,247/QALY since 2014, highly variable between therapeutic areas (rare diseases showed the highest levels, exceeding €1 million). Lastly, the time required for CEESP appraisals has increased significantly since 2022, reaching almost 8 months in 2024.
CONCLUSIONS: CEESP's activity has seen a decrease in issued opinions since 2023, along with extended evaluation delays. The high rate of invalidated opinions underscores the importance of methodological rigor and reducing uncertainty in submitted CUA, making the use of CEESP's economic opinions challenging, if not leveraged at all, within price negotiation in France. This highlights the need to improve integrating and interpreting economic analysis in pricing negotiations, now a priority for stakeholders in France.
METHODS: Data were extracted from the IQVIA's internal exhaustive database covering CEESP’s opinions published between 2014 and 31st December 2024. The analysis included number and types of evaluations, therapeutic areas and in-depth description of methodological reservations or global major uncertainty as defined by the CEESP’s doctrine.
RESULTS: Since 2014, CEESP has published 236 opinions with an average of 21 opinions per year, predominantly on medicines and vaccines (91%). A downward trend is observed since 2023 related to changes in eligibility criteria. Furthermore, 41% of the medicines and vaccines cost-utility analysis (CUA) were invalidated since 2014: 34% due to major methodological reservations (primarily related to clinical data integration and utility scores measurement) and 7% due to global major uncertainty. For validated CUA, the median ICER was €126,247/QALY since 2014, highly variable between therapeutic areas (rare diseases showed the highest levels, exceeding €1 million). Lastly, the time required for CEESP appraisals has increased significantly since 2022, reaching almost 8 months in 2024.
CONCLUSIONS: CEESP's activity has seen a decrease in issued opinions since 2023, along with extended evaluation delays. The high rate of invalidated opinions underscores the importance of methodological rigor and reducing uncertainty in submitted CUA, making the use of CEESP's economic opinions challenging, if not leveraged at all, within price negotiation in France. This highlights the need to improve integrating and interpreting economic analysis in pricing negotiations, now a priority for stakeholders in France.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HTA20
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas